Search results
AstraZeneca completes Fusion Pharmaceuticals acquisition
Pharmaceutical Technology via Yahoo Finance· 1 day agoAstraZeneca has announced the conclusion of its acquisition of clinical-stage biopharmaceutical...
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 23 hours agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
Nucleus RadioPharma secures Series A investment from AstraZeneca
BioPharma-Reporter· 5 hours agoThe investment from AstraZeneca marks a strategic move to further expand Nucleus's capabilities in developing targeted radiotherapies and theranostics, aimed at making cancer ...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 1 day agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 6 hours agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 1 day agoOn Monday, Deutsche Bank (ETR:DBKGn) reiterated a Hold rating and a price target of GBP110.00 on...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 1 day agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 15 hours agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 2 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...